1. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136(1): 125-135.

2. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, Park WS, Yoo NJ, Liu ET, Miller LD, Lee JY. Molecular changes from dysplastic nodule to hepatocellular carci noma through gene expression profiling. Hepatology 2005; 42(4): 809-818.

3. Panga R, Tsea E, Poon RTP. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006; 240(2): 157-169.

4. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carci noma. J Exp Med 1998; 188(2): 341-350.

5. Li B, Gao B, Ye L, Han X, Wang W, Kong L, Fang X, Zeng Y, Zheng H, Li S, Wu Z, Ye L. Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 path ways of unfolded protein response. Virus Res 2007; 124(1-2): 44-49.

6. Cougot D, Neuveut C, Buendia MA. HBVinduced carcinogenesis. J Clin Virol 2005; 34(Suppl 1): S75-S78.

7. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006; 147(2): 58-66.

8. Cha C, DeMatteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005; 19(1): 25-37.

9. Feitelson MA. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett 2006; 239(1): 10-20.

10. Wei W, Huang W, Pan Y, Zhu F, Wu J. Functional switch of viral protein HBx on cell apoptosis, transfor ma tion, and tumorigenesis in association with oncoprotein Ras. Cancer Lett 2006; 244(1):119-128.

11. Kang-Park S, Lee JH, Shin JH, Lee YI. Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42 map kinase signalings. Biochem Biophys Res Commun 2001; 283(2): 303-307.

12. Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modu lates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res 2006; 122(1-2): 53-60.

13. Henkler F, Hoare J, Waseem N, Goldin RD, McGarvey MJ, Koshy R, King IA. Intracellular localiza tion of the hepatitis B virus HBx protein. J Gen Virol 2001; 82: 871-882.

14. Kim KM, Kwon S-N, Kang J-I, Lee SH, Jang SK, Ahn B-Y, Kim YK. Hepatitis C virus NS2 protein acti vates cellular cyclic AMP-dependent pathways. Biochem Biophys Res Commun 2007; 356(4):948–954.

15. Baek K-H, Park H-Y, Kang C-M, Kim S-J, Jeong S-J, Hong E-K, Park J-W, Sung Y-C, Suzuki T, Kim C-M, Lee C-W. Overexpression of hepatitis C birus NS5A pro tein induces chromosome instability via mitotic cell cycle dysregulation. J Mol Biol 2006; 359(1): 22-34.

16. Wang J, Tong W, Zhang X, Chen L, Yi Z, Pan T, Hu Y, Xiang L, Yuan Z. Hepatitis C virus nonstructural protein NS5A interacts with FKBP38 and inhibits apop tosis in Huh7 hepatoma cells. FEBS Lett 2006; 580(18): 4392-4400.

17. Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, Grosso LE, Ray RB, Ray R. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virol ogy 2006; 349(2):347-358.

18. Nguyen H, Sankaran S, Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virol ogy 2006; 354(1): 58-68.

19. Wang J-S, Groopman JD. DNA damage by myco toxins. Mutat Res 1999; 424(1-2): 167-181.

20. Jackson PE, Groopman JD. Aflatoxin and liver cancer. Bailliere’s Clin Gastroenterol 1999; 13(4): 545-555.

21. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dom inant Role of Hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36(5):1214-1220.

22. Asare GA, Bronz M, Naidoo V, Kew MC. Interac tions between aflatoxin B1 and dietary iron overload in hepatic mutagenesis. Toxicology 2007; 234(3): 157-166.

23. Long XD, Ma Y, Wei YP, Deng ZL. The polymor phisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res 2006; 36(1): 48-55.

24. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127(5): S87-S96.

25. Balasubramaniyan V, Shukla R, Murugaiyan G, Bhonde RR, Nalini N. Mouse recombinant leptin protects human hepatoma HepG2 against apoptosis, TNF-á response and oxidative stress induced by the hepatotoxin-ethanol. Biochim Biophys Acta 2007; 1770(8): 1136-1144.

26. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003; 34(1): 1-10.

27. McKillop IH, Schrum LW. Alcohol and liver can cer. Alcohol 2005; 35(3): 195-203.

28. Hsiang C-Y, Wu S-L, Chen J-C, Lo H-Y, Li C-C, Chiang S-Y, Wu H-C, Ho T-Y. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-êB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett 2007; 171(1-2): 78-86.

29. Djordjevi. D, Nikoli. J, Stefanovi. V. Ethanol interactions with other cytochrome P450 substrates includ ing drugs, xenobiotics, and carcinogens. Pathol Biol 1998; 46(10): 760-70.

30. Buendia MA. Genetics of hepatocellular carci noma. Semin Cancer Biol 2000; 10(3):185-200.

31. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepato cellular carcinoma. Semin Liver Dis 2007; 27(1): 55-76.

32. Nishimura T, Nishida N, Komeda T, Fukuda Y, Ikai I, Yamaoka Y, Nakao K. Genome-wide semiquan titative microsatellite analysis of human hepatocellular carcinoma: discrete mapping of smallest region of overlap of recurrent chromosomal gains and losses. Cancer Genet Cytogenet 2006; 167(1): 57-65.

33. Buendia, MA. Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol 2007; 46(4): 546-548.

34. Pogribny IP, James SJ. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without cod ing region mutation. Cancer Lett 2002; 176(2): 169-174.

35. Calvisi DF, Conner EA, Ladu S, Lemmer ER, Factor VM, Thogeirsson SS. Activation of the canonical Wnt/â-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. J Hepatol 2005; 42(6):842-849.